This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...
Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Labcorp LH has announced enhancements to Global Trial Connect, a suite of digital, data and operational solutions aimed at increasing the speed of clinical trials at the heart of clinical research ...
Patients who took a single high dose of GUBamy lost 3% of their body weight during the 6-week trial, while those on a placebo ...
The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.
Labcorp LH has announced enhancements to Global Trial Connect, a suite of digital ... beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these ...
Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after ... disclosed the trial results in August.